(MDLN) Medline Common Stock - Overview
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 31.296m USD | Total Return: -8.5% in 12m
Avg Turnover: 297M
Rev. Trend: 99.9%
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Medline Inc. (MDLN) is a global manufacturer and distributor of medical-surgical products serving the full continuum of healthcare, including hospitals, surgery centers, and post-acute facilities. The company operates through two primary segments: Medline Brand, which focuses on proprietary manufacturing of surgical, diagnostic, and patient-care supplies, and Supply Chain Solutions, which manages third-party distribution and logistics optimization.
The healthcare supplies sector is characterized by high barriers to entry due to complex regulatory requirements and the necessity for extensive distribution networks. Medline employs a vertically integrated business model, allowing it to capture margins both as a manufacturer of private-label goods and as a logistics partner for national brands. This dual approach helps mitigate supply chain volatility while providing comprehensive inventory management for healthcare providers.
Investors may find it useful to review the latest valuation metrics on ValueRay to further assess the companys market position. Headquartered in Northfield, Illinois, the company has maintained operations since 1966, expanding from domestic manufacturing into international clinical and diagnostic markets.
- In-house manufacturing margins drive profitability relative to third-party distribution
- Expansion into post-acute and nursing home facilities captures aging demographic trends
- Global supply chain logistics efficiency impacts segment operating income volatility
- High demand for infection control and PPE products stabilizes recurring revenue
- Capital expenditure for surgical solutions manufacturing influences long-term free cash flow
| Net Income: 964.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 0.00 > 1.0 |
| NWC/Revenue: 29.66% < 20% (prev 22.86%; Δ 6.80% < -1%) |
| CFO/TA 0.04 > 3% & CFO 1.52b > Net Income 964.0m |
| Net Debt (10.4b) to EBITDA (2.94b): 3.53 < 3 |
| Current Ratio: 4.41 > 1.5 & < 3 |
| Outstanding Shares: last quarter (825.0m) vs 12m ago 3.15% < -2% |
| Gross Margin: 24.04% > 18% (prev 0.25%; Δ 2.38k% > 0.5%) |
| Asset Turnover: 77.71% > 50% (prev 70.90%; Δ 6.82% > 0%) |
| Interest Coverage Ratio: 2.64 > 6 (EBITDA TTM 2.94b / Interest Expense TTM 763.0m) |
| A: 0.22 (Total Current Assets 11.2b - Total Current Liabilities 2.54b) / Total Assets 39.0b |
| B: 0.00 (Retained Earnings 122.0m / Total Assets 39.0b) |
| C: 0.05 (EBIT TTM 2.01b / Avg Total Assets 37.5b) |
| D: 0.01 (Book Value of Equity 140.0m / Total Liabilities 19.7b) |
| Altman-Z'' = 1.83 = BBB |
| DSRI: 1.00 (Receivables 3.67b/3.22b, Revenue 29.1b/25.5b) |
| GMI: 1.03 (GM 24.04% / 24.66%) |
| AQI: 0.94 (AQ_t 0.59 / AQ_t-1 0.63) |
| SGI: 1.14 (Revenue 29.1b / 25.5b) |
| TATA: -0.01 (NI 964.0m - CFO 1.52b) / TA 39.0b) |
| Beneish M = -2.95 (Cap -4..+1) = A |
As of May 27, 2026, the stock is trading at USD 36.16 with a total of 14,668,356 shares traded.
Over the past week, the price has changed by +0.39%,
over one month by -20.05%,
over three months by -26.04% and
over the past year by -8.46%.
Medline Common Stock has no consensus analysts rating.
P/E Trailing = 32.4649
P/E Forward = 25.0627
P/S = 1.074
P/B = 2.7764
Revenue TTM = 29.1b USD
EBIT TTM = 2.01b USD
EBITDA TTM = 2.94b USD
Long Term Debt = 12.5b USD (from longTermDebt, last quarter)
Short Term Debt = 77.0m USD (from shortTermDebt, last quarter)
Debt = 12.6b USD (from shortLongTermDebtTotal, last quarter) + Leases 65.0m
Net Debt = 10.4b USD (calculated: Debt 12.6b - CCE 2.24b)
Enterprise Value = 41.7b USD (31.3b + Debt 12.6b - CCE 2.24b)
Interest Coverage Ratio = 2.64 (Ebit TTM 2.01b / Interest Expense TTM 763.0m)
EV/FCF = 27.34x (Enterprise Value 41.7b / FCF TTM 1.52b)
FCF Yield = 3.66% (FCF TTM 1.52b / Enterprise Value 41.7b)
FCF Margin = 5.23% (FCF TTM 1.52b / Revenue TTM 29.1b)
Net Margin = 3.31% (Net Income TTM 964.0m / Revenue TTM 29.1b)
Gross Margin = 24.04% ((Revenue TTM 29.1b - Cost of Revenue TTM 22.1b) / Revenue TTM)
Gross Margin QoQ = 22.65% (prev 24.58%)
Tobins Q-Ratio = 1.07 (Enterprise Value 41.7b / Total Assets 39.0b)
Interest Expense / Debt = 6.04% (Interest Expense 763.0m / Debt 12.6b)
Taxrate = 17.87% (52.0m / 291.0m)
NOPAT = 1.65b (EBIT 2.01b * (1 - 17.87%))
Current Ratio = 4.41 (Total Current Assets 11.2b / Total Current Liabilities 2.54b)
Debt / Equity = 1.12 (Debt 12.6b / totalStockholderEquity, last quarter 11.3b)
Debt / EBITDA = 3.53 (Net Debt 10.4b / EBITDA 2.94b)
Debt / FCF = 6.82 (Net Debt 10.4b / FCF TTM 1.52b)
Total Stockholder Equity = 14.0b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.57% (Net Income 964.0m / Total Assets 39.0b)
RoE = 6.87% (Net Income TTM 964.0m / Total Stockholder Equity 14.0b)
RoCE = 7.59% (EBIT 2.01b / Capital Employed (Equity 14.0b + L.T.Debt 12.5b))
RoIC = 4.53% (NOPAT 1.65b / Invested Capital 36.5b)
WACC = 7.99% (E(31.3b)/V(43.9b) * Re(9.22%) + D(12.6b)/V(43.9b) * Rd(6.04%) * (1-Tc(0.18)))
Discount Rate = 9.22% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 45.36 | Cagr: 2.72%
[DCF] Terminal Value 76.50% ; FCFF base≈1.48b ; Y1≈1.59b ; Y5≈1.93b
[DCF] Fair Price = 22.68 (EV 29.6b - Net Debt 10.4b = Equity 19.2b / Shares 845.6m; r=8.35% [WACC [floored]]; 5y FCF grow 8.54% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 99.91 | Revenue CAGR: 10.63% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.32 | Chg30d=-2.95% | Revisions=-52% | Analysts=22
EPS next Quarter (2026-09-30): EPS=0.38 | Chg30d=+3.11% | Revisions=+36% | Analysts=21
EPS current Year (2026-12-31): EPS=1.51 | Chg30d=+2.69% | Revisions=+54% | GrowthEPS=-15.9% | GrowthRev=+9.4%
EPS next Year (2027-12-31): EPS=1.66 | Chg30d=+0.55% | Revisions=+17% | GrowthEPS=+10.2% | GrowthRev=+12.5%
[Analyst] Revisions Ratio: +54%